Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

Tuesday, September 14, 2021
Webinar -- 5:00 PM ET


This program was approved by the IASLC 2021 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2021 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Welcome and Introduction

Overview of Immunotherapy in Nonmetastatic NSCLC – Jarushka Naidoo, MB BCH BAO, MHS

  • Optimal use of immunotherapy in stage III NSCLC
  • New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC

Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC – Julie Brahmer, MD, MSc

  • Current immunotherapy landscape in advanced NSCLC
  • Immune resistance and sequencing of therapy
  • Emerging biomarkers of response to ICI therapy in NSCLC

Immunotherapyin Advanced or Metastatic NSCLC: Special Populations – Jarushka Naidoo, MB BCH BAO, MHS

  • Response to ICI-based therapy in patients with cachexia
  • ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation

Final Panel Discussion and Audience Question and Answer Session


Program Director
Julie Brahmer, MD, MSc

Professor of Oncology
Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in immuno-oncology for the treatment of non-small-cell lung cancer.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal first-line immune checkpoint inhibitor and chemotherapy combinations for patients with advanced or metastatic NSCLC
  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC
  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy and in those who are ineligible for surgery or chemoradiation therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
  • Address factors that have the potential to reduce efficacy of ICI therapy in individual patients with NSCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.